Delivery Order SPE2DB22D3011-SPE2DB25FQ1DV
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $5,248.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a competitively awarded non-set-aside contract. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $4,275.96 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This firm fixed price delivery order, which is scheduled for completion by September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded a $5,103.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on September 22, 2025, with completion scheduled for September 23, 2025. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order valued at $26,707.66 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on September 26, 2025, with completion scheduled for September 29, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $42,081.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a completion date of September 16, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,340.26 on September 17, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections. The contract utilizes firm fixed-price pricing with no set-aside designation and is scheduled for completion by September 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $29,522.73 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen injectors, with an ultimate completion date of June 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ1DVDelivery Order
The Defense Logistics Agency awarded a $4,345.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 mL pen injections, with an ultimate completion date of June 9, 2025. This competitively awarded contract, issued without set-aside designation, leverages AmerisourceBergen's established relationship with DLA as a critical pharmaceutical distributor supporting federal medical procurement. The contract represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the company's primary vehicle for delivering comprehensive pharmaceutical and medical supply solutions to military healthcare systems globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to federal healthcare customers including the Defense Health Agency and U.S. Coast Guard. The delivery of Zepbound, a GLP-1 receptor agonist used for weight management, reflects the company's role in supplying specialty medications and diabetes-related treatments to support military personnel and veteran healthcare needs. The firm fixed-price structure and competitive award demonstrate AmerisourceBergen's capability to meet federal procurement standards in the open market.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 6/6/25 |